Jersey City, NJ, Aug. 14, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market (By Product (VOWST (SER-109), REBYOTA, Visbiome, Other Pipeline Products), By Target Disease Indication (Recurrent C. Difficile Infection, Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), Antibiotic-Associated Diarrhea (AAD), Pouchitis, Hepatic Encephalopathy (HE), Graft Versus Host Disease, Necrotizing Enterocolitis, Primary Hyperoxaluria, Other Indications), By route of administration (Oral therapeutics, Rectal therapeutics))- Market Outlook and Industry Analysis 2031"
According to the company's newest research, the Global Live Biotherapeutic Product (LBP) Market is predicted to grow at CAGR of 21.2 % between 2023 and 2031.
Free PDF Report Brochure @ https://www.insightaceanalytic.com/request-sample/1300
Live Biotherapeutics are a recognized new class of medicines which contains live organisms, such as bacteria. These live microbiome drugs can prevent, treat and cure the disease conditions of humans and potentially transform how we treat many diseases. These therapeutics do not contain any vaccine category. These microbes produce and consume numerous compounds that considerably impact our health and well-being. The reintroduction of beneficial microorganisms has the potential to act as clinically relevant therapies to re-establish and maintain a healthy microbiome. Importantly, LBPs will also have a biological impact by affecting the local ecosystem, other microbes, and their interactions with the host.
Over the forecast period, market growth is anticipated to be driven by expanding research and development efforts as well as a growing pipeline of microbiome-targeting therapies that are anticipated to treat a wide range of serious diseases.
The market is developing due to increasing innovation and technological developments in developing new pharmaceuticals and clinical trial activities for illness treatment. During the forecast period, significant growth opportunities are anticipated due to rising government funding and an increased R&D budget for drug development. Over 640 patents focused on microbiome therapeutics were approved in during last 2 years.
Challenges related to ensuring compliance with good manufacturing practices (GMP), Associated Safety Issues with LBPs and capacity include limited availability of expertise, a lack of specialized infrastructure which need for excessive capital investment, and the requirement for high capital expenditure. These factors are expected to restrain the growth of the market. However, due to rising demand for new novel drugs and the significant burden of bacterial infection disease, North America is expected to experience rapid growth during the forecast period (2023-2031). Companies receive enormous funding for product development and research on Live Biotherapeutic ingredients.
Key developments in the market:
- In Mar 2022, Microbiotica has accomplished a £50 million ($67 million) Series B financing round, the largest microbiome-related financing round in Europe to date. The assets will also be used to advance Microbiotica's two lead oral Live Bacterial Therapeutics (LBTs), MB097 and MB310, to Phase 1b clinical trials, as well as LBTs in new disease areas.
- In Nov 2021, Together by collaboration, Bacthera and Seres Therapeutics will commercially manufacture SER-109, a possible cure for recurrent C. difficile infection. According to the terms of the contract, Bacthera will build a special facility for commercial production in its new facility Microbiome Center of Excellence on Lonza's Ibex campus in Visp, Switzerland that is devoted to the production of LBPs.
- In Aug 2021, Finch Therapeutics announced that the development of the FIN-524 Ulcerative Colitis Program will be accelerated its strategic partner Takeda. Prior to the anticipated start of clinical-stage development, Takeda will take over primary development responsibility for the programme, which is now known as TAK-524. With the change, Takeda will be able to use its knowledge of inflammatory bowel disease (IBD) for the duration of the clinical development of FIN-524/TAK-524.
- In Nov 2020, ExeGi Pharma declares EXE-346 Live Biotherapeutic an FDA orphan drug. Drugs and biological products designed to treat diseases that affect fewer than 200,000 patients in the US are given some advantages thanks to this designation. An LBP called EXE-346 has a fixed-proportion of 8 live probiotic bacterial strains that are meant to be taken orally.
Some Of The Key Players In The Live Biotherapeutic Product (LBP) Market:
- Seres Therapeutics, Inc.
- Microbiotica
- Enterome
- Destiny Pharma plc
- Taisho Pharmaceutical Holdings
- AOBiome Therapeutics, Inc.
- Finch Therapeutics Group, Inc
- Ferring Pharmaceuticals
- Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
- MaaT Pharma
- Vedanta Biosciences Inc.
- OxThera AB
- Pendulum Therapeutics
- Caelus Health
- Quorum Innovations
- Sanofi S.A
- DermBiont, Inc.
- EnteroBiotix Ltd
- YSOPIA Bioscience
- Winclove Probiotics
- TargEDys
- Evelo Biosciences, Inc.
- BiomX
- Biomica Ltd.
- Scioto Biosciences, Inc.
- Lactobio A/S
- Takeda Pharmaceutical Co. Ltd.
- Second Genome Therapeutics
- Johnson and Johnson Inc.
- Kaleido Biosciences Inc.
- OptiBiotix Health Plc
- PureTech Health Plc
- Immuron Limited
- Naked Biome
- Synthetic Biologics
- ExeGi Pharma
- Nexbiome
- Mybiotics Pharma LTD.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1300
Market Segmentation
Global Live Biotherapeutic Product (LBP) Market, by Product, 2023-2031 (Value US$ Mn)
- VOWST (SER-109)
- REBYOTA
- Visbiome
- Other Pipeline Products
Global Live Biotherapeutic Product (LBP) Market, by Target Disease Indication, 2023-2031 (Value US$ Mn)
- Recurrent C. Difficile Infection
- Irritable Bowel Syndrome (IBS)
- Ulcerative Colitis (UC)
- Antibiotic-Associated Diarrhea (AAD)
- Pouchitis
- Hepatic Encephalopathy (HE)
- Graft Versus Host Disease
- Necrotizing Enterocolitis
- Primary Hyperoxaluria
- Other Indications
Global Live Biotherapeutic Product (LBP) Market, by Route of Administration, 2023-2031 (Value US$ Mn)
- Oral Therapeutics
- Rectal Therapeutics
Global Live Biotherapeutic Product (LBP) Market, by Region, 2023-2031 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Live Biotherapeutic Product (LBP) Market, by Country, 2023-2031 (Value US$ Mn)
- U.S.
- Canada
Europe Live Biotherapeutic Product (LBP) Market, by Country, 2023-2031 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Live Biotherapeutic Product (LBP) Market, by Country, 2023-2031 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Live Biotherapeutic Product (LBP) Market, by Country, 2023-2031 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Live Biotherapeutic Product (LBP) Market, by Country, 2023-2031 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Check Discount on the Report @ https://www.insightaceanalytic.com/discount/1300
About Us:
InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.
Follow Us @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Subscribe Our Exclusive Newsletters @ https://www.linkedin.com/newsletters/latest-market-research-reports-6929319878155739136/
